Goldline Pharmaceutical SME IPO
Alloted
Goldline Pharmaceutical Limited, incorporated in 2021, is a pharmaceutical marketing company that operates under an asset-light business model. The company markets a wide range of pharmaceutical formulations under its proprietary brand 'Goldline', across five specialized divisions: Pharma (General), Cardinal (Specialty), Aayushman (Pediatric), InLife (Critical Care), and Wellness (Supportive Care). Instead of in-house manufacturing, Goldline partners with 15 third-party manufacturers and utilizes a network of 7 distributors to supply products to retailers and hospitals across Maharashtra, Tamil Nadu, Rajasthan, and other states.
Issue Price
43
Current GMP
₹15 (34.88%)
Overall Subscription
840.81x
Issue Size
₹11.61 Cr
Advertisement
Live Subscription by Application
| Category | Applications Offered | Applications Received | Subscription |
|---|---|---|---|
| QIB | 180 | 85 | 0.47x |
FII | - | 23 | - |
DFI | - | 1 | - |
MF | - | 0 | - |
Other | - | 61 | - |
| NII | 43 | 33,760 | 785.12x |
bNII | 29 | 20,429 | 704.45x |
Corporate | - | 172 | - |
Individual | - | 20,021 | - |
Other | - | 236 | - |
sNII | 14 | 13,331 | 952.21x |
Corporate | - | 54 | - |
Individual | - | 13,153 | - |
Other | - | 124 | - |
| IND | 150 | 1,32,173 | 881.15x |
Fixed price | - | 1,32,173 | - |
| Total | 373 | 1,66,018 | 445.09x |
Live Subscription by Shares
| Category | Shares Offered | Shares Applied | Subscription |
|---|---|---|---|
| QIB | 5.40 L | 9.73 Cr | 180.22x |
FII | - | 2.54 Cr | - |
DFI | - | 9.00K | - |
MF | - | 0 | - |
Other | - | 7.19 Cr | - |
| NII | 3.90 L | 64.83 Cr | 1662.39x |
bNII | 2.60 L | 51.89 Cr | 1995.67x |
Corporate | - | 44.79 L | - |
Individual | - | 50.87 Cr | - |
Other | - | 57.21 L | - |
sNII | 1.30 L | 12.95 Cr | 995.84x |
Corporate | - | 5.16 L | - |
Individual | - | 12.78 Cr | - |
Other | - | 11.73 L | - |
| IND | 9.00 L | 79.30 Cr | 881.15x |
Fixed price | - | 79.30 Cr | - |
| Total | 18.30 L | 153.87 Cr | 840.81x |
Subscription Summary
QIB
Shares Applied:180.22x
Applications Offered:0.47x
NII
Shares Applied:1662.39x
Applications Offered:785.12x
IND
Shares Applied:881.15x
Applications Offered:881.15x
Quick Stats
Total Categories3
IPO TypeSME
StatusAllotment Out
Join us on Telegram for instant IPO updates!
Join NowData Last Updated
15 May 2026, 01:28 pm
Auto-refreshing
Advertisement
Understanding Subscription Categories
QIB
Qualified Institutional Buyers
Includes FII, DFI, Mutual Funds, and other qualified institutions.
NII
Non-Institutional Investors
High net-worth individuals: bNII (₹10L+) and sNII (₹2L-₹10L).
IND
Individual Investors
Individual investors in SME IPOs up to ₹2 lakh.
Frequently Asked Questions
What is the current subscription status of Goldline Pharmaceutical SME?
The current overall subscription for Goldline Pharmaceutical SME is 840.81x. This indicates the total demand relative to the shares offered. Higher subscription typically suggests strong investor interest.
How to check Goldline Pharmaceutical SME subscription status?
You can check Goldline Pharmaceutical SME subscription status on IPOwiz, BSE website, NSE website, or your broker's platform. Subscription data is updated regularly during the IPO period from 12 May 2026 to 14 May 2026.
What do subscription numbers mean?
Subscription numbers show how many times the IPO is oversubscribed. For example, 840.81x means the IPO received 840.81x times more applications than shares available. Higher subscription in retail category generally means lower allotment chances.
When does Goldline Pharmaceutical SME subscription close?
The subscription for Goldline Pharmaceutical SME closes on 14 May 2026. Applications must be submitted before the closing time on this date. Late applications will not be accepted.
What is the difference between QIB, NII, and Individual (IND) subscription?
QIB (Qualified Institutional Buyers) includes mutual funds, FIIs, and other institutions. NII (Non-Institutional Investors) includes high net-worth individuals investing above ₹2 lakh. Individual (IND) includes individual investors with applications up to ₹2 lakh. Each category has separate subscription quotas.
How does subscription affect allotment chances?
Higher subscription in your category means lower allotment chances. For example, if retail subscription is 840.81x, it means there are 840.81x times more applications than shares available, making allotment competitive.
When will Goldline Pharmaceutical SME allotment be finalized?
The allotment for Goldline Pharmaceutical SME will be finalized and announced on 15 May 2026. You can check your allotment status on the registrar's website, BSE, NSE, or your demat account after this date.
What happens after subscription closes?
After subscription closes on 14 May 2026, the company and registrar process all applications. Allotment is finalized by 15 May 2026, and shares are credited to successful applicants' demat accounts before the listing date on 19 May 2026.
Can I apply after subscription closes?
No, you cannot apply after the subscription closes on 14 May 2026. All IPO applications must be submitted during the subscription period from 12 May 2026 to 14 May 2026. Late applications are automatically rejected.
What is the issue size and lot size for Goldline Pharmaceutical SME?
The issue size for Goldline Pharmaceutical SME is ₹11.61 Cr, and the lot size is 3000 shares. The price range is ₹41.0 - ₹43.0. You must apply in multiples of the lot size.